Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas

International Journal of Cancer

Volumn 119, Issue 6, 2006, Pages 1303-1311

  Adachi, Yasuo ^a   Aoki, Chieko ^a   Yoshio Hoshino, Naoko ^a   Takayama, Koichi ^b   Curiel, David T ^c   Nishimoto, Norihiro ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c University of Alabama at Birmingham   (United States)

Author keywords

Adenovirus; Humanized antibody to human IL 6 receptor (tocilizumub, currently known as MRA); Interleukin 6 (IL 6); Mesothelioma; Vascular endothelial growth factor (VEGF)

Indexed keywords

ADENOVIRUS VECTOR; ATLIZUMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN; VASCULOTROPIN;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; IMMUNE RESPONSE; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; MEDIATOR RELEASE; MOLECULAR GENETICS; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; MESOTHELIOMA; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33747493036     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22006     Document Type: Article

References (46)

1. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer 1982;49:2431-5.
2. Kindler HL, Vogelzang NJ. Mesothelioma: are we making progress? Semin Oncol 2002;29:1.
3. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM. DeCamp MM, Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.
4. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17.
5. Aldieri E, Orecchia S, Ghigo D, Bergandi L, Riganti C, Fubini B, Betta PG, Bosia A. Simian virus 40 infection down-regulates the expression of nitric oxide synthase in human mesothelial cells. Cancer Res 2004;64:4082-4.
6. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995;12:455-60.
7. Versnel MA, Claesson-Welsh L, Hammacher A, Bouts MJ, van der Kwast TH, Eriksson A, Willemsen R, Weima SM, Hoogsteden HC, Hagemeijer A, Heldin C-H. Human malignant mesothelioma cell lines express PDGF β-receptors whereas cultured normal mesothelial cells express predominantly PDGF α-receptors. Oncogene 1991;6:2005-11.
8. Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA, Burt M, Rom WN. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor 1 and associated molecules. Cancer Res 1993;53:2858-64.
9. Morocz IA, Schmitter D, Lauber B, Stahel RA. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor α/epidermal growth factor receptor mitogenic pathway. Br J Cancer 1994;70:850-6.
10. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin-8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999;59:367-71.
11. Monti G, Jaurand M-C, Monnet I, Chretien P, Saint-Etienne L, Zeng L, Portier A, Devillier P, Galanaud P, Bignon J, Emilie D. Intrapleural production of interleukin-6 during mesothelioma and its modulation by 7-interferon treatment. Cancer Res 1994;54:4419-23.
12. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hichlin DJ, Putnam JB, Jr, Ellis LM. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 11:3364-8.
13. __ 13. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, Pass HI. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61.
14. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75.
15. Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003;104:603-10.
16. Nakano T, Chahinian AP, Shinjo M. Tonomura A, Miyake M, Togawa N, Ninomiya K, Higashino K. Interleukin-6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77:907-12.
17. Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BWS, Fitzpatrick DR. Interleukin-6 involvement in mesothelioma pathology, inhibition by Interferon α immunotherapy. Cancer Immunol Immunother 1995;40:241-50.
18. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J 2003;374:1-20.
19. Hirano T. Molecular basis underlying functional pleiotropy of cytokines and growth factors. Biochem Biophys Res Commun 1999;260:303-8.
20. Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the angiogenic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002;1592:251-63.
21. Nishimoto N, Ito A, Ono M, Tagoh H, Matsumoto T, Tomita T, Ochi T, Yoshizaki K. IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patient in the presence of soluble IL-6 receptor. Int Immunol 2000;12:187-93.
22. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9.
23. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM et al. Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8.
24. Wei L-H, Kuo M-L, Chen C-A, Chou C-H, Lai K-B, Lee C-N, Hsieh C-Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003;22:1517-27.
25. Shimizu S, Hirano T, Yoshioka R, Sugai S, Matsuda T, Taga T, Kishimoto T, Konda S. Interleukin-6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3). Blood 1988;72:1826-8.
26. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cell in vitro. Cancer Res 1997;57:141-6.
27. Arcari P, Martinelli R, Salvatore F. The complete sequence of a full-length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res 1984;12:9179-89.
28. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-46.
29. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiently to ovarian cancer cells. Clin Cancer Res 2002;8:275-80.
30. Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, Hirota H, Izumi M, Yoshizaki K, Walsh K, Kishimoto T, Yamauchi-Takihara K. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 2000;275:10561-6.
31. Maizel JV, Jr, White DO, Scharff MD. The polypeptides of adenovirus I: evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968;36:115-25.
32. Szczepek AJ, Belch AR, Pilarski LM. Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma. Exp Hematol 2001;29:1076-81.
33. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA. Concentration and origins of soluble interleukin-6 receptor-α in serum and synovial fluid. J Rheumatol 1997;24:1510-16.
34. Nishimoto N, Sasaki M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
35. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC. IL-6 triggers cell growth via the Ras-dependent mirogen-activated protein kinase cascade. J Immunol 1997;159:2212-21.
36. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jova R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
37. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000.
38. Horita K, Inase N, Miyake S, Formby B, Toyoda H, Yoshizawa Y. Progesterone induces apoptosis in malignant mesothelioma cells. Anticancer Res 2001;21:3871-4.
39. Marklund L, Henriksson R, Grankvist K. Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide. Int J Cancer 2001;93:577-83.
40. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 1998;157:1616-22.
41. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
42. Olsen NJ, Stein M. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
43. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993;82:1120-6.
44. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998;161:6347-55.
45. Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H, Shiraishi N, Raje N, Kumar S, Picker DH, Jacob GS, Richardson PG et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005;105:4470-6.
46. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2004;50:1761-9.